Trial Profile

Safety and efficacy of rifaximin added to lactulose in patients with overt hepatic encephalopathy: A real world study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifaximin (Primary) ; Lactulose
Indications Hepatic encephalopathy
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 Apr 2019 New trial record
15 Apr 2019 According to a Norgine media release, this investigator-initiated study was sponsored by the Foundation for Liver and Gastrointestinal Research Rotterdam (SLO) and supported by an educational grant from Norgine B.V., Amsterdam, the Netherlands.
15 Apr 2019 According to a Norgine media release, results from this study were presented today at the International Liver Congress (ILC) 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com